|  |  |  |
| --- | --- | --- |
|  | **The Hong Kong Neurosurgical Society Limited**  **& Hong Kong Neurosurgical Society**  **28th Annual Scientific Meeting**  **26th & 27th November 2021** |  |
|  |  |

***ABSTRACT FORM***

Abstract submission deadline: 10th September 2021

Please submit your abstract by e-mail to [hoht@ha.org.hk](mailto:hoht@ha.org.hk) using the format as in the sample.

**<PRESENTING AUTHOR>**

**Title (tick) :**  □ Mr. □ Ms. ✔︎ Dr. □ Prof./Associate Prof.

|  |  |  |  |
| --- | --- | --- | --- |
| **Surname : Ho** | | **Given Name(s) : Cheuk Him** | |
|  | |  | |
| **Department : Neurosurgery** | | | |
|  | |  | |
| **Institution : Queen Mary Hospital** | | | |
|  | |  | |
| **Telephone: 9826 8885** | **Fax : /** | | **E-mail : andrew94@connect.hku.hk** |

**Status :**  ✔︎ Member □ Affiliate Member

□ Non-member ( □ Doctor / □ Nurse / □ Research Assistant /

□ Medical Student)

□ Others \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Form of presentation desired:**

✔︎ Oral presentation

□ Poster presentation

□ Either Oral or Poster presentation

□ Video presentation (submit an abstract with a video (≤ 3 minutes))

**Date:** 10th September 2021

**PLEASE NOTE THAT THIS IS A TEMPLATE. YOU MAY SAVE YOUR FILE IN ANOTHER NAME IN WORD FORMAT USING TIMES NEW ROMAN FONT SIZE 10 & SINGLE LINE SPACING**

|  |
| --- |
| **Title:**  **The Role of Transamin in Treating Chronic Subdural Haematoma**  **Authors: HO, Cheuk Him1, LI, Lai Fung, LUI, Wai Man1**  **Institution(s):**  **1Division of Neurosurgery, Department of Surgery, Queen Mary Hospital, Hong Kong.**  **Background**  **Chronic subdural haematoma (CSDH) is a common neurosurgical condition, especially in the elderly. With an aging population, the incidence of CSDH is expected to rise. Burr-hole is the mainstay of evacuating CSDH causing mass effect. The post-operative recurrence rate is commonly reported at 10-30%. In the last decade, transamin (tranexamic acid) is increasingly being recognised as being a safe and effective adjunct in manging intracranial haemorrhage, especially in the setting of neuro-trauma. This study aims to evaluate the effectiveness and safety of transamin in the setting of CSDH as it is a common condition in elderly patients who are predisposed to thromboembolic complications due to their comorbidities. The roles of anti-platelet and anti-coagulation therapy in contributing towards recurrence or thromboembolic events were also evaluated.**  **Method**  **This is a single-centre, retrospective study. Patient list was retrieved from the departmental database using ICD codes. All patients who underwent burr-hole during 2015-2019 for evacuation of chronic subdural haematoma were included in the study. Patients under the age of 18 were excluded.**  **Results**  **295 patients were included in the study. 67.8% (200/295) of patients received transamin peri-operatively. No significant difference in thromboembolic complications or recurrence rate was identified between the groups. 36.6% (108/295) of patients were on anti-platelet or anti-coagulant at the time of their presentation. Patients on warfarin were associated with significantly higher risks of having thromboembolic events in the peri-operative period. (9.5% vs 0.75%; p=0.001)**  **Conclusion**  **The use of transamin is safe. Peri-operative interruption or reversal of warfarin needs to be balanced against the risks of thromboembolism. Further study is required to evaluate the effectiveness of transamin in treating chronic subdural haematoma.** |